MARKET

FPRX

FPRX

Five Prime
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.45
+0.22
+3.53%
Closed 16:42 07/08 EDT
OPEN
6.24
PREV CLOSE
6.23
HIGH
6.74
LOW
6.03
VOLUME
531.02K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.750
MARKET CAP
236.30M
P/E (TTM)
-1.8547
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FPRX stock price target is 8.40 with a high estimate of 11.00 and a low estimate of 5.00.

EPS

FPRX News

More
How R&D Expenses Can Help You Pick Outperforming Stocks
Seeking Alpha - Article · 6d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
Is Five Prime Therapeutics Inc (FPRX) Going to Burn These Hedge Funds?
Insider Monkey · 06/26 14:17
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
NVTA, ATHX, BBGI and AFH among midday movers
Seeking Alpha - Article · 06/22 16:39
Why Five Prime's Stock Is Trading Higher Today
Benzinga · 06/22 15:48
Why Five Prime's Stock Is Trading Higher Today
Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.
Benzinga · 06/22 14:48
Wedbush Upgrades Five Prime Therapeutics to Outperform, Raises Price Target to $9
Wedbush analyst Robert Driscoll upgrades Five Prime Therapeutics (NASDAQ:FPRX) from Neutral to Outperform and raises the price target from $5 to $9.
Benzinga · 06/22 11:26

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About FPRX

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
More

Webull offers kinds of Five Prime Therapeutics Inc stock information, including NASDAQ:FPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FPRX stock methods without spending real money on the virtual paper trading platform.